Jan 2 2021
Here are the responses to our December, 2020 Quick Question: “What therapeutic does your center use for hemophilia A patients with inhibitors who bleed during emicizumab therapy?” There were only 6 voters
- Activated prothrombin complex concentrate [APCC]: 0
- Recombinant activated factor VII [rFVIIa]: 4
- Low-dose factor VIII: 1
- High-dose factor VIII: 0
- None, we see no bleeds: 1
Our new “ReCaptcha” function, designed to trap spam, slowed our December voting, however it appears that recombinant activated factor VII [NovoSeven, rFVIIa] is the treatment of choice. Thank you for your votes.
Comments (0)Bleeding Disorders
No comments here.